TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36175917
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN) administered for 12 weeks, followed by an additional 12 weeks for all participants.
Study: 33592280
Drug: Magnetic enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic enteric-coated tablet containing diclofenac sodium
Study: 33592280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (before domperidone administration)
Study: 35894933
Drug: Glimepiride 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 0.5 mg once daily
Study: 35474624
Drug: CBT4BN (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4BN (internet-based cognitive-behavioral therapy)
Study: 35474624
Drug: CBTF2F (face-to-face
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTF2F (face-to-face cognitive-behavioral therapy)
Study: 33989559
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks combined with cetuximab 400 mg/m2 intravenously (initial loading dose) followed by 250 mg/m2 intravenously weekly.
Study: 33989559
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks combined with cetuximab 400 mg/m2 intravenously followed by 250 mg/m2 intravenously weekly.
Study: 34705542
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g of FO n3 supplementation
Study: 33299400
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) plus physical therapy
Study: 35245011
Drug: PEG-rhGH 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.20 mg/kg/w
Study: 35245011
Drug: daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily rhGH 0.28 mg/kg/w
Study: 32746639
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light (BWL) for 30 minutes daily for 8 weeks
Study: 32746639
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (DRL) for 30 minutes daily for 8 weeks
Study: 32294620
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with intentional hydration (1 L of water the previous night, 500 mL 60 min before intervention, and 1 mL for each 1 g of body mass lost immediately after intervention)
Study: 36286665
Drug: Glucocorticosteroid hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticosteroid hormones (GCS), specifically dexamethasone, used as an anti-inflammatory treatment for critically ill patients with COVID-19.
Study: 32311799
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens combined with trastuzumab
Study: 34396874
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg 1 hour before surgery
Study: 33427559
Drug: Increased dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased dietary phosphorus intake (100 mg)
Study: 34486986
Drug: Istradefylline 40
Normalized name: istradefylline 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline 40 mg/day
Study: 35200040
Drug: Warfarin, clopidogrel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin, clopidogrel, and aspirin
Study: 36307892
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) - 5 fractions of 8 Gy
Study: 33331206
Drug: SHR0534 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0534 at doses of 10, 25, 50, or 100 mg
Study: 33331206
Drug: SHR0534 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0534 at 5 mg
Study: 35798138
Drug: Cassia fistula
Normalized name: CASSIA FISTULA FRUIT
DrugBank: Cassia fistula fruit (DB15860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cassia fistula syrup (CFS)
Study: 33766820
Drug: Standard breakthrough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard breakthrough medication administered by healthcare professionals
Study: 32310680
Drug: 0.05% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% w/w ECa 233 gel
Study: 35984704
Drug: CT900 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT900 at a dose of 12 mg/m2/q2Wk
Study: 32482970
Drug: Guanfacine Extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine Extended Release (GXR) 1-7 mg/d
Study: 32789935
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) adjunctive to conventional therapy, 30 sessions, twice daily over 3 weeks (group A)
Study: 33915011
Drug: Discharge care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge care bundle including medication reconciliation, counselling session and documentation transfer to primary care physician (PCP)
Study: 33971837
Drug: Specific vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific vaccines (Polio, BCG, DPT (1-3), Measles)
Study: 32144493
Drug: Spot urinary
Normalized name: Cold Spot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spot urinary sodium excretion (high: UNa+ > 50 or low: ≤ 50 mEq/L) at 2 h from furosemide administration
Study: 33065643
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) consisting of 2 cycles of docetaxel plus cisplatin and 5-fluorouracil (DCF)
Study: 32135413
Drug: Pegbovigrastim (IMR)
Normalized name: pegbovigrastim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbovigrastim (IMR) treatment (2.7 mL of Imrestor)
Study: 32135413
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) treatment (2.7 mL of 0.9% saline)
Study: 33471429
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with conventional therapy (systemic antibiotics and trazodone)
Study: 33471429
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (laser/LEDs off) with conventional therapy (systemic antibiotics and trazodone)
Study: 33471429
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (laser/LEDs off)
Study: 34876098
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group
Study: 33370348
Drug: Cysteamine 450mg
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine 450mg twice daily
Study: 34088727
Drug: Bronchial artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchial artery embolisation (BAE) associated with medical therapy
Study: 34746903
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg
Study: 33055588
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (VG) - 1 mg each of three epitope peptides injected postoperatively 10 times weekly followed by 10 times biweekly.
Study: 34092822
Drug: SPN-812 400-mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 400-mg/day
Study: 34092822
Drug: SPN-812 600-mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 600-mg/day
Study: 34518679
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (4.5×10^5, 9.0×10^5, or 1.8×10^6 doses)
Study: 34518679
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (1.8×10^6 dose)
Study: 34518679
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (9.0×10^5 dose)
Study: 35254888
Drug: dd-MVAC (dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: dd-MVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Study: 33454768
Drug: Early anti-androgen
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early anti-androgen treatment
Study: 33454768
Drug: Late anti-androgen
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late anti-androgen treatment
Study: 33095658
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy (active device) for 3 hours per day for 4 weeks
Study: 36011679
Drug: Microcurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent therapy
Study: 35361646
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (300 g/day containing 106 CFU/g Lactobacillus acidophilus and Bifidobacterium lactis)
Study: 35361646
Drug: Plain yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain yoghurt (300 g/day)
Study: 34693434
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of orthodontic force (Group B)
Study: 34716979
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (pegylated liposomal doxorubicin [40 or 50 mg/m2], topotecan [1.25 mg/m2], paclitaxel [80 mg/m2], or gemcitabine [1000 mg/m2])
Study: 33076866
Drug: Genotypic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic resistance testing (GRT) to inform onward treatment
Study: 35904580
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg, oral)
Study: 32307624
Drug: Full-dose ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose ketamine (0.5 mg kg‐1 initial bolus, 10 mcg kg‐1 min‐1 infusion)
Study: 33856973
Drug: Forgiveness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forgiveness therapy
Study: 35488019
Drug: High subcutaneous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High subcutaneous adipose tissue radiation attenuation (SAT-RA Z-score)
Study: 35220182
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every three weeks for one year)
Study: 35220182
Drug: β-blockers (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (oral administration within 30 days of randomisation)
Study: 35220182
Drug: Pembrolizumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab with β-blockers
Study: 35220182
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with β-blockers
Study: 35220182
Drug: Pembrolizumab without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab without β-blockers
Study: 32985064
Drug: High-dose THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose THC (20 or 25 mg)
Study: 33220252
Drug: Anti-H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H pylori therapy
Study: 36423863
Drug: Online self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-administered cognitive behavioral therapy with guided peer support
Study: 36423863
Drug: Therapist-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-administered cognitive behavior therapy
Study: 33470139
Drug: Cenobamate (CNB)
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cenobamate (CNB) as adjunct therapy
Study: 33812743
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of 13-valent pneumococcal conjugate vaccine (PCV13)
Study: 34815165
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders for medication intake (first to seventh postoperative days)
Study: 34468869
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W for up to 35 cycles
Study: 33864481
Drug: Neck‐worn position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck‐worn position therapy device (PTD)
Study: 32549196
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance (OA)
Study: 35001638
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg daily)
Study: 32560746
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (Pulmozyme®, Roche, Switzerland) administered by aerosol, at a dose of 2500 IU twice daily for 7 consecutive days.
Study: 35351187
Drug: Accelerometer measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerometer measured average daily minutes of brisk walking (≥ 100 steps/min)
Study: 36433662
Drug: Bioactive collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive collagen peptides (CP) 15 g daily
Study: 34535037
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg bid
Study: 32386271
Drug: Bipolar sealing
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar sealing device (BSD) with suture augmentation (4-0 polydioxanone)
Study: 32386271
Drug: Bipolar sealing
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar sealing device (BSD) without suture augmentation
Study: 33325259
Drug: HI-FIVES intervention
Normalized name: Eucalyptus dives leafy twig oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: HI-FIVES intervention (three weekly facilitated training calls covering five education topics)
Study: 33836878
Drug: Tocilizumab at
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab at 8 mg/kg on day -1 and abatacept at 10 mg/kg on days 0, 7, 14, and 28
Study: 33836878
Drug: Historical cohort
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical cohort received rabbit ATG at 5 mg/kg total dose
Study: 33810804
Drug: Transcutaneous tibial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous tibial nerve stimulation (TTNS) therapy
Study: 32412598
Drug: Theracurmin® (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theracurmin® (360 mg/day)
Study: 34096894
Drug: Exemestane treatment
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane treatment
Study: 33462653
Drug: Annual zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Annual zoledronic acid (ZOL) infusion (5 mg) at 1 week, 12 months, and 24 months after surgery
Study: 89120227
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone treatment
Study: 32272518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CaHA and MFU-V
Study: 32660282
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg every-8-weeks
Study: 33123819
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of caffeine
Study: 35831082
Drug: Short list
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short list of essential medicines
Study: 33836963
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (L group)
Study: 34153231
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction adalimumab (2·4 mg/kg at weeks 0 and 1)
Study: 34153231
Drug: Standard-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose induction adalimumab (2·4 mg/kg at week 0 and placebo at week 1)
Study: 34153231
Drug: Standard-dose maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose maintenance adalimumab (0·6 mg/kg every other week)
Study: 34153231
Drug: Pooled adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pooled adalimumab groups (high-dose and standard-dose)
Study: 35057489
Drug: 5.5 g
Normalized name: honey 5.5 gram/5 mL ORAL SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5 g of BiotisTM GOS
Study: 34117528
Drug: 3× weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3× weekly bicycle ergometer training during HD for 12 weeks
Study: 32371534
Drug: Standard-of-care medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care medical treatment (MED)
Study: 35275009
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (ISCL)
Study: 34582448
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil (SSO) emollient therapy; 10 ml applied 3 times daily throughout the neonatal period.
Study: 34814835
Drug: Expert-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert-based medication review
Study: 33941123
Drug: Work-related medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-related medical rehabilitation program (at least 11 hours of work-related treatment modules)
Study: 33151615
Drug: 0.05% tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tomato lycopene and 3.45% wheat bran extract cream applied twice a day for three months with SPF 30 sunscreen
Study: 33151615
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice a day for three months with SPF 30 sunscreen
Study: 35428645
Drug: Digital behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital behavioural health treatment for chronic pain
Study: 33809130
Drug: Flaxseed (FS)
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (FS) dietary intervention, 10 g/d for 6 weeks
Study: 32088670
Drug: Eucalyptus solution
DrugBank: Eucalyptus gum (DB15537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucalyptus solution 5% inhalation 3 times/day for 20 minutes (every 8 hours)
Study: 36482231
Drug: 2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/kg alfentanil
Study: 36482231
Drug: 4 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg/kg alfentanil
Study: 36482231
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of alfentanil (2, 3, 4 μg/kg)
Study: 35688164
Drug: tixagevimab-cilgavimab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tixagevimab-cilgavimab 600 mg (two consecutive 3 mL intramuscular injections, 300 mg tixagevimab and 300 mg cilgavimab)
Study: 35688164
Drug: tixagevimab-cilgavimab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tixagevimab-cilgavimab 600 mg
Study: 32334703
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg or 600 mg loading dose, then 75 mg once daily for 12 months)
Study: 32334703
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose, then 90 mg twice daily for 12 months)
Study: 36254029
Drug: Religious Rational
Normalized name: red delicious apple allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religious Rational Emotive Behavior Therapy (RREBT) for 12 weeks
Study: 33034015
Drug: Intra-gastric balloon
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-gastric balloon (IGB) therapy
Study: 34676663
Drug: Ibrexafungerp (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrexafungerp (300 mg twice for 1 day)
Study: 35783610
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy
Study: 35783610
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no convalescent plasma therapy)
Study: 33901921
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factors (G-CSF)
Study: 35059803
Drug: 70 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 kVp tube voltage, Smart mA for noise index (NI) of 36HU, contrast dose rate of 16mgI/kg/s, and DLIR-H
Study: 35059803
Drug: 120 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 kVp, Smart mA for NI of 25HU, contrast dose rate of 32mgI/kg/s, and 60% ASIR-V
Study: 35987298
Drug: Generic cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic cognitive‐behavioral therapy (CBT) treatment
Study: 35987298
Drug: Modified (social
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified (social anxiety) treatment
Study: 33151330
Drug: No insomnia
Approvals — FDA: no, EMA: no, PMDA: no
Description: No insomnia treatment
Study: 32598468
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus nicotine gum (8 weeks)
Study: 32598468
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus nicotine gum (26 weeks)
Study: 32738019
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (intervention group) for 6 months
Study: 34587567
Drug: Intermittent theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent theta burst stimulation (iTBS) to the cerebellar midline, administered 5 times/week for 2 weeks.